Corticotropin Releasing Factor (CRF) Activation of NF-κB-Directed Transcription in Leukocytes

  title={Corticotropin Releasing Factor (CRF) Activation of NF-$\kappa$B-Directed Transcription in Leukocytes},
  author={Eric M. Smith and M Gregg and Farhad B Hashemi and Liesl Schott and Thomas K. Hughes},
  journal={Cellular and Molecular Neurobiology},
Summary1. [] Key Method Initially, we examined the ability of CRF to modulate an antigen-specific, in vitro antibody response. Since that could be mediated by NF-κB transcription factor activity, we tested CRF in a NF-κB driven luciferase gene expression reporter assay.2. CRF enhanced the antigen-specific antibody production in a dose- and time-dependent manner. RAW 264.7 macrophage cells and splenocytes stained by immunohistochemistry were positive for CRF receptors and CRF. Expression of both was up…
Identification of new Rel/NFκB regulatory networks by focused genome location analysis
Six previously unrecognized NF-κB controlled genes (ATM, EP300, TGFβ, Selectin, MMP-1, and SFN) were identified and a coregulatory role for Ets transcription factors in the expressed genes was predicted by comparative promoter analysis and confirmed by ChIP and by functional disruption of Ets.
Murine splenic B cells express corticotropin-releasing hormone receptor 2 that affect their viability during a stress response
It is demonstrated, for the first time, that CRH is able to modulate directly B cell activity through the presence of CRHR2, and this receptor is functional since CRH treatment of B cells activates different signaling pathways and decreases B cell viability.
Notoginsenoside R1 improves monocrotaline-induced pulmonary arterial hypertension via modulation NF-κB signaling in rats
NGR1 exerts ameliorative effects on MCT-induced PAH by inhibiting NF-κB pathway, therefore, NGR1 may be a new potential therapy for PAH.
The corticotropin releasing factor system in cancer: expression and pathophysiological implications
The literature suggesting that the CRF system could be involved in the regulation of human cancer development is reviewed, finding potential implication in growth, metastasis, angiogenesis, or immune parameters via activation of locally expressed receptors could be clinically exploited by presenting targets of new therapeutic approaches.
Role of Ginkgolides in the Inflammatory Immune Response of Neurological Diseases: A Review of Current Literatures
The studies on the roles of ginkgolides in inflammatory immunomodulation are reviewed and its potential role in novel treatments for neurological diseases is suggested.
Discovery of a stable tripeptide targeting the N-domain of CRF1 receptor.
It is proposed that (R)-LMI can be used as an optimal lead compound in the rational design of novel CRF antagonists, and likely blocked agonist actions by interacting with the N-domain of CRF1R as suggested by data using a constitutively active chimera of CRFs.
Chronic Stress, Inflammation, and Colon Cancer: A CRH System-Driven Molecular Crosstalk
Current knowledge is summarized that supports the inseparable link between chronic stress, inflammation, and colorectal cancer (CRC), by modulation of a cascade of molecular signaling pathways, which are under the regulation of CRH-family members expressed in the brain and periphery.


Regulation of nuclear factor-kappaB by corticotropin-releasing hormone in mouse thymocytes.
It is shown that CRH-deficient mice respond to lipopolysaccharide administration by reduced activation of thymus NF-kappaB, despite their significantly elevated proinflammatory cytokine and their low corticosterone levels, which suggest a putative molecular pathway mediating the proinflammatory effects of peripheral CRH through induction of the NF- kappaB DNA binding activity.
Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes.
Corticotropin-releasing hormone-dependent stimulation of NF-kappaB activity is consistent with accumulated data about role of this neuropeptide in the regulation of local epidermal homeostasis.
Receptor-mediated immunomodulation by corticotropin-releasing factor.
Corticotropin-releasing factor receptor 1 in mouse spleen: expression after immune stimulation and identification of receptor-bearing cells.
It was indicated that CRF-R1 was not produced constitutively by mature or immature neutrophils, its production was rather triggered by inflammatory stimuli.
Function and activation of NF-kappa B in the immune system.
The inhibition of NF-kappa B activation by antioxidants and specific protease inhibitors may provide a pharmacological basis for interfering with these acute processes in suppressing toxic/septic shock, graft-vs-host reactions, acute inflammatory reactions, severe phase response, and radiation damage.
Inhibition of NF-kappa B by sodium salicylate and aspirin.
The anti-inflammatory drugs sodium salicylate and aspirin inhibited the activation of NF-kappa B, which further explains the mechanism of action of these drugs.
Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids.
It is shown that the synthetic glucocorticoid dexamethasone induces the transcription of the I kappa B alpha gene, which results in an increased rate of I k Kappa B alpha protein synthesis, which is predicted to markedly decrease cytokine secretion and thus effectively block the activation of the immune system.
Stimulation of interleukin-6 production by corticotropin-releasing factor.
Immunosuppression by Glucocorticoids: Inhibition of NF-κB Activity Through Induction of IκB Synthesis
It is shown that glucocorticoids are potent inhibitors of nuclear factor kappa B activation in mice and cultured cells, mediated by induction of the IκBα inhibitory protein, which traps activated NF-κB in inactive cytoplasmic complexes.